The annual Santa Barbara Great Strides walk is a step around the corner and participating teams have already entered the race ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger. Vertex's push ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...

The global APOL1-mediated kidney disease market is poised for substantial expansion, with projections indicating a remarkable ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...